NIH-funded research R01 grant

How body fat affects skin leishmaniasis outcomes

Official title: Adipocytes and inflammation in the cutaneous leishmaniasis outcome

Funded at Federal University of Bahia · NIH-11173606 · Data updated 2026-11-12

This project looks at how fat tissue and fat-related molecules change inflammation and healing in people with cutaneous leishmaniasis, especially those who are overweight or obese.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionFederal University of Bahia
NIH-funded
Lab location1 site (Salvador, Brazil)
Project startAugust 20, 2024
Project endJuly 31, 2029
Funding year2025
Award (this year)$120,226
NIH project number5R01AI183392-02
Project IDNIH-11173606 on NIH RePORTER

Who could benefit from this research

Could help

Adults with cutaneous leishmaniasis, particularly those who are overweight or obese, would be the primary candidates for participation.

Less likely to help

People without cutaneous leishmaniasis, those with other forms of leishmaniasis, or people unable to provide blood or tissue samples are unlikely to see direct benefit from this work.

What this research studies

You would be asked to give blood and, when possible, small samples of fat and skin so researchers can study immune cells, leptin, and lipid profiles. The team will compare obese and non-obese patients to see whether different fats or higher leptin levels link with worse skin ulcers and slower healing. Laboratory tests will also test whether certain lipids can shift macrophages from an inflammatory state toward a tissue-repair state. Findings will be compared with treatment results to look for links between fat, inflammation, and therapy failure.

Why it matters

Potential benefit: If successful, this work could point to ways to reduce harmful inflammation and help skin ulcers heal faster in people with cutaneous leishmaniasis.

How similar studies have gone: Some prior studies link obesity and leptin to stronger inflammation, but using lipid profiling and macrophage reprogramming to improve cutaneous leishmaniasis outcomes is a relatively new approach.

Where this research is happening

  • Federal University of Bahia
    Salvador, Brazil
    Active

Researchers

  • Principal investigator: Carvalho, Lucas P — Federal University of Bahia
  • Study coordinator: Carvalho, Lucas P

Related research

Other NIH-funded projects on the same topics.

  • Adipose tissue and inflammation in cutaneous leishmaniasis

    This grant explores how fat tissue and inflammatory signals affect skin ulcers in people with cutaneous leishmaniasis, aiming to uncover why obesity may worsen the disease.

    NIH research Federal University of Bahia · Salvador, Brazil · NIH-11398866

  • How fat cells and inflammation affect skin infections caused by Leishmania

    This study is looking at how being overweight might affect the healing of a skin infection called cutaneous leishmaniasis, by checking how fat cells and inflammation work together, and it aims to find ways to help people with this condition heal better and faster.

    NIH research Federal University of Bahia · Salvador, Brazil · NIH-10897397

  • Examining how social factors and healthcare programs affect HIV/AIDS in Brazil

    This study looks at how things like money support, healthcare access, and social factors affect people living with HIV/AIDS in Brazil, aiming to find ways to improve their health and treatment outcomes.

    NIH research Federal University of Bahia · Salvador, Brazil · NIH-10817035

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.